-
Dec 2, 2024 | 
ionanalytics.com | Sam Kerr |Rachel Lewis |Taku Dzimwasha |Lloyd Vassell
Large-cap exits have been notoriously difficult for European private equity (PE) firms in 2024, and a tough selling environment is leading several sponsors, and other issuers, to pull the trigger on public listings instead. This news service has previously reported on the average holdings for private equity hitting a new five-year high in 2024, as PEs have been unable to find buyers for assets at a price that generates the return general partners (GPs) want and limited partners (LPs) expect.
-
Nov 28, 2024 | 
ionanalytics.com | Myriam Mariotte |Rachel Lewis |Lloyd Vassell
PAI Partners is expected to start exploring options for StellaGroup, a France-based window manufacturer, towards the latter half of next year, according to two sources familiar with the situation. The company, which also produces shutters, curtains, gates and doors is already working with advisors, one source added. It registered EUR 120m EBITDA in 2023 and could be valued at least EUR 1.6bn, the second source said.
-
Nov 26, 2024 | 
reba.global | Rachel Lewis
Writing REBA’s trilogy, Societal health shifts: the impact on workplace health strategy, Rachel Lewis, director, professional doctorate of organisational psychology at Birkbeck, University of London, details how to integrate prevention into your wellbeing strategy.
-
Nov 18, 2024 | 
ionanalytics.com | Taku Dzimwasha |Rachel Lewis |Christel Thunell |Raj Saiya
Stada Arzneimittel AG’s long-anticipated listing could be the tonic healthcare IPOs need to supercharge volumes again. As previously reported, the German pharma heavyweight, backed by Bain and Cinven, is pressing ahead with its IPO plans for next year, raising optimism for the healthcare sector. In 2024 YTD, healthcare IPOs have reached USD 3.7bn, this is up from USD 2.5bn in 2023. Volumes this year were boosted by the IPO of Galderma [SIX: GALD] in March; a USD 2.6bn deal.
-
Nov 15, 2024 | 
ionanalytics.com | Rachel Lewis |Izaz Ansari |Lloyd Vassell
Some of Europe’s largest private equity firms, once renowned for multi-billion buyouts, are increasingly seeing that bigger is not always better. Sponsors including KKR, EQT, CVC, Permira, and others, have all dropped the average size of their global deals over the past five years, and especially when compared to the heady days of 2021.
-
Nov 11, 2024 | 
ionanalytics.com | Sam Kerr |Rachel Lewis |Christel Thunell |Lloyd Vassell
Investors focusing on large-cap listings likely to get index inclusionMid-cap IPO candidates must be cheap or uniqueSponsors focusing on middle market with large-cap financing difficultA new structural dynamic appeared in the European capital markets in 2024, one that is predicted to continue into 2025, of a disparity in strategic options available for sellers of large and mid-cap companies.
-
Oct 14, 2024 | 
ionanalytics.com | Rachel Lewis |Samantha Shaji |Lloyd Vassell
Vendors await better trading numbers, macro conditions before launching salesAuction process lengthening, bidders take time for diligence, financingSome quick exits, but most take longer than 6 monthsVendors and their sellside advisors have just one or two weeks left to launch European auctions if they hope to close before Christmas. The pool of potential deals is large: over a third of all auctions tracked by Mergermarket are sitting in the pre-launch stage.
-
Aug 6, 2024 | 
ionanalytics.com | Claude Risner |Rachel Lewis |Lloyd Vassell
Palamon Capital Partners has appointed Morgan Stanley to advise on an upcoming auction for its portfolio company MyDentist, the UK’s largest dental chain, according to three sources familiar with the situation. Formerly known as Integrated Dental Holdings (IDH), MyDentist runs nearly 550 dental clinics across the UK, with more than four million patients.
-
Jul 15, 2024 | 
ionanalytics.com | Sam Kerr |Rachel Lewis |Taku Dzimwasha |Lloyd Vassell
Is this the way Europe’s 2024 IPO year ends? Not with a bang but with a whimper. Everyone in equity capital markets, including ECM Pulse, hopes not, but a string of IPO failures pre-summer and a hollowing out of the post-summer calendar is cause for concern, especially as private equity starts to stretch its muscles again. A blockbuster pipeline has slowly been whittled down, as some sellers move closer to private exit solutions for their assets.
-
May 27, 2024 | 
ionanalytics.com | Nelson Rodrigues |Rachel Lewis |Christel Thunell |Iñaki Miguel
News (Intelligence) The sale of FairJourney Biologics has moved to the second round and the company has attracted the interest of private equity firms Advent International and KKR & Co [NYSE:KKR], sources familiar with the situation said. The Portuguese contract research organisation (CRO), backed by specialist healthcare sponsor GHO Capital, had mandated JP Morgan earlier this year, as reported.
